Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.62%
#2 Luxxcoin Luxxcoin +45.27%
#3 ResearchCoin ResearchCoin +22.78%
#4 Reactive Network Reactive Network +20.67%
#5 Orderly Network Orderly Network +16.77%
#6 Layer3 Layer3 +13.71%
#7 Bitgert Bitgert +13.08%
#8 Aria.AI Aria.AI +11.86%
#9 Useless Coin Useless Coin +9.66%
#10 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.53%
Coin of the day
Resolv wstUSR Resolv wstUSR
Instellingen
Taal
DUTCH
Valuta
USD
Thema
CSL Limited CSL Limited

CSL Limited

CSL
Rang in aandelen #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Aandeelprijs
$99.32
Marktkapitalisatie
$48.20B
Verandering (1 dag)
0.98%
Verandering (1 jaar)
-32.14%
Land
AU
Handel CSL Limited (CSL)

Categorie

Healthcare
Omzet van CSL Limited (CSL)
Omzet in Dec 2025 TTM: $15.70B
Volgens de laatste financiële rapporten van CSL Limited bedraagt de huidige omzet van het bedrijf (TTM) $15.70B. In 2024 behaalde het bedrijf een omzet van $14.69B een stijging ten opzichte van de omzet in het jaar 2023, die $13.17B bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van CSL Limited van 2000 tot 2026
Omzet aan het einde van elk jaar
Jaar Omzet Wijzigen
2026 (TTM) $15.70B 1.72%
2025 $15.43B 5.04%
2024 $14.69B 11.51%
2023 $13.17B 25.55%
2022 $10.49B 1.56%
2021 $10.33B 9.84%
2020 $9.41B 13.08%
2019 $8.32B 11.54%
2018 $7.46B 6.28%
2017 $7.02B 15.81%
2016 $6.06B 11.00%
2015 $5.46B 8.91%
2014 $5.01B 10.79%
2013 $4.52B -2.44%
2012 $4.64B -3.37%
2011 $4.80B 49.63%
2010 $3.21B 6.25%
2009 $3.02B -7.53%
2008 $3.26B 42.87%
2007 $2.28B 45.52%
2006 $1.57B -1.58%
2005 $1.60B 98.59%
2004 $803.28M 36.45%
2003 $588.71M 38.88%
2002 $423.90M -2.21%
2001 $433.49M 0.00%
2000 0.00 0.00%
Omzet van vergelijkbare bedrijven of concurrenten
Bedrijf Omzet Omzetverschil Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.55B 209.32%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B -23.30%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B -8.62%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -42.13%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B -65.01%
NL